AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29316895 — intervention group
Group type: COMPARATOR
Intervention: Sham RSS (control)
Number of subjects: 71
Study 26979999 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement pain and movement fatigue
Number of subjects: 94
Study 26979999 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement pain and fatigue
Number of subjects: 94
Study 26979999 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement fatigue
Number of subjects: 94
Study 24875670 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-intensity walking at 3.2 km/h every 20 min
Number of subjects: 19
Study 24875670 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity walking at between 5.8 and 6.4 km/h every 20 min
Number of subjects: 19
Study 24875670 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting
Number of subjects: 19
Study 22997495 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U BoNT‐A
Number of subjects: 34
Study 22997495 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U BoNT‐A
Number of subjects: 34
Study 19239933 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical preparation of the colon (MPC)
Number of subjects: 193
Study 19239933 — intervention group
Group type: COMPARATOR
Intervention: No mechanical preparation of the colon (No-MPC)
Number of subjects: 193
Study 19239933 — intervention group
Group type: EXPERIMENTAL
Intervention: Colocolic anastomosis (MPC)
Number of subjects: 193
Study 19239933 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal anastomosis (MPC)
Number of subjects: 193
Study 17606560 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone treatment
Number of subjects: 360
Study 15356500 — intervention group
Group type: EXPERIMENTAL
Intervention: Haas appliance
Number of subjects: 19
Study 15356500 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyrax appliance
Number of subjects: 19
Study 15356500 — intervention group
Group type: COMPARATOR
Intervention: Both appliances
Number of subjects: 19
Study 11427643 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux haemodialysis (Low-HD, n=10)
Number of subjects: 39
Study 11427643 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux haemodialysis (High-HD, n=10)
Number of subjects: 39
Study 11427643 — intervention group
Group type: EXPERIMENTAL
Intervention: Online haemodiafiltration (HDF, n=10)
Number of subjects: 39
Study 11427643 — intervention group
Group type: EXPERIMENTAL
Intervention: Online haemofiltration (HF, n=9)
Number of subjects: 39
Study 9886106 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (Thai Government Pharmaceutical Organization) 40 mg/kg
Number of subjects: 95
Study 9886106 — intervention group
Group type: COMPARATOR
Intervention: Biltricide 40 mg/kg
Number of subjects: 95
Study 9700743 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-4 (0.5 mg/h)
Number of subjects: 0
Study 9700743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2916453 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children
Number of subjects: 0
Study 2916453 — intervention group
Group type: COMPARATOR
Intervention: Lean children
Number of subjects: 0
Study 2916453 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese children after 6 months of treatment
Number of subjects: 0
Study 2916453 — intervention group
Group type: COMPARATOR
Intervention: Lean children after 6 months of treatment
Number of subjects: 0
Study 2916453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups after 6 months
Number of subjects: 0
Study 343992 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 mg tolmetin daily for 2 weeks
Number of subjects: 64
Study 343992 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ketoprofen daily for 2 weeks after 1 week on placebo
Number of subjects: 64
Study 343992 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 week
Number of subjects: 64
Study 343992 — intervention group
Group type: COMPARATOR
Intervention: 600 mg tolmetin daily for 2 weeks
Number of subjects: 64
Study 31823525 — intervention group
Group type: COMPARATOR
Intervention: Tropifexor (LJN452) 10-3000 µg single ascending doses (SAD)
Number of subjects: 95
Study 31823525 — intervention group
Group type: COMPARATOR
Intervention: Tropifexor (LJN452) 10-100 µg multiple ascending doses (MAD)
Number of subjects: 95
Study 31823525 — intervention group
Group type: COMPARATOR
Intervention: Tropifexor (LJN452) 300 µg with a high-fat meal
Number of subjects: 95
Study 31823525 — intervention group
Group type: COMPARATOR
Intervention: Tropifexor (LJN452) vs placebo in obese subjects
Number of subjects: 95
Study 31823525 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropifexor (LJN452)
Number of subjects: 95
Study 31099803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention (individual counseling and pamphlet)
Number of subjects: 80
Study 31099803 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 80
Study 28705995 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal continuous positive airway pressure (CPAP) device
Number of subjects: 0
Study 28705995 — intervention group
Group type: COMPARATOR
Intervention: HRCT imaging
Number of subjects: 0
Study 25895447 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with 5-fluorouracil plus cisplatin
Number of subjects: 164
Study 23935969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 40 mg/m² every 3 weeks (Group A)
Number of subjects: 64
Study 23935969 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixabepilone 20 mg/m² on days 1, 8, and 15 every 4 weeks (Group B)
Number of subjects: 64
Study 23935969 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study 21871987 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 1433
Study 21871987 — intervention group
Group type: COMPARATOR
Intervention: No mechanical bowel preparation (No MBP)
Number of subjects: 1433
Study 19046971 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube feeding
Number of subjects: 15
Study 19046971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined feedings (tube feeding + oral feeding)
Number of subjects: 15
Study 19046971 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined feedings
Number of subjects: 15
Study 16891292 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate (400 mg/d) for 6 months
Number of subjects: 186
Study 14763913 — intervention group
Group type: EXPERIMENTAL
Intervention: GH replacement therapy (GHRT) at a starting dose of 0.45 IU (0.15 mg)/day, increased to 0.9 IU (0.30 mg)/day in month 2, and maintained at 2 IU (0.66 mg)/day
Number of subjects: 14
Study 14763913 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls matched for age, education, and sex)
Number of subjects: 14
Study 11740294 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 weeks of supervised circuit training (combined aerobic and resistance exercise)
Number of subjects: 19
Study 8989178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and enteral ofloxacin-amphotericin B (group B)
Number of subjects: 660
Study 8989178 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and enteral polymyxin E-tobramycin-amphotericin B (group C)
Number of subjects: 660
Study 8989178 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic regimen (control group A)
Number of subjects: 660
Study 8120739 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa/carbidopa (20/5 mg)
Number of subjects: 10
Study 8120739 — intervention group
Group type: COMPARATOR
Intervention: placebo (20 mg)
Number of subjects: 10
Study 3314221 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent, live attenuated intranasally administered influenza A vaccine
Number of subjects: 55
Study 3314221 — intervention group
Group type: COMPARATOR
Intervention: Inactivated, parenterally administered influenza A vaccine
Number of subjects: 55
Study 29502281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive narrative therapy intervention (four sessions: decision, subjectivation, metaphorization, projecting)
Number of subjects: 91
Study 29502281 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 91
Study 27796912 — intervention group
Group type: EXPERIMENTAL
Intervention: Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg/day
Number of subjects: 1747
Study 27796912 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg/day
Number of subjects: 1747
Study 26132682 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 150
Study 26132682 — intervention group
Group type: COMPARATOR
Intervention: Minimal Acupuncture
Number of subjects: 150
Study 26132682 — intervention group
Group type: COMPARATOR
Intervention: Placebo Acupuncture
Number of subjects: 150
Study 22812251 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-keto/amino acid supplemented low protein diet
Number of subjects: 23
Study 22812251 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes diet
Number of subjects: 23
Study 20735827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice intervention (6 weeks, delivered by physiotherapists and occupational therapists)
Number of subjects: 16
Study 20735827 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory part of the intervention
Number of subjects: 16
Study 20735827 — intervention group
Group type: EXPERIMENTAL
Intervention: Optional part of the intervention
Number of subjects: 16
Study 18719318 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin + thienopyridine
Number of subjects: 32
Study 18719318 — intervention group
Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 32
Study 15942767 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent inspiratory and expiratory muscle training (CRMT)
Number of subjects: 34
Study 15942767 — intervention group
Group type: COMPARATOR
Intervention: Sham CRMT
Number of subjects: 34
Study 15942767 — intervention group
Group type: EXPERIMENTAL
Intervention: CRMT (differing intensities)
Number of subjects: 34
Study 12759480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery
Number of subjects: 1218
Study 12759480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (subgroup with predominantly upper-lobe emphysema and low exercise capacity)
Number of subjects: 1218
Study 12759480 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1218
Study 10484859 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine to Methadone ratio
Number of subjects: 0
Study 10484859 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone to Methadone ratio
Number of subjects: 0
Study 10484859 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pain syndromes
Number of subjects: 0
Study 8984866 — intervention group
Group type: EXPERIMENTAL
Intervention: (1.5 x ED95 mivacurium) + (0.5 x ED95 rocuronium)
Number of subjects: 0
Study 8984866 — intervention group
Group type: EXPERIMENTAL
Intervention: (1 x ED95 mivacurium) + (1 x ED95 rocuronium)
Number of subjects: 0
Study 8984866 — intervention group
Group type: EXPERIMENTAL
Intervention: (0.5 x ED95 mivacurium) + (1.5 x ED95 rocuronium)
Number of subjects: 0
Study 8984866 — intervention group
Group type: EXPERIMENTAL
Intervention: (2 x ED95 mivacurium)
Number of subjects: 0
Study 8984866 — intervention group
Group type: EXPERIMENTAL
Intervention: (2 x ED95 rocuronium)
Number of subjects: 0
Study 8984866 — intervention group
Group type: COMPARATOR
Intervention: mivacurium alone
Number of subjects: 0
Study 8984866 — intervention group
Group type: COMPARATOR
Intervention: rocuronium alone
Number of subjects: 0
Study 1752109 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.003 mg/kg
Number of subjects: 6
Study 1752109 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.007 mg/kg
Number of subjects: 6
Study 1752109 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.02 mg/kg
Number of subjects: 6
Study 1752109 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (all doses)
Number of subjects: 6
Study 6242491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care interventions in the perinatal period
Number of subjects: 0
Study 6242491 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care in Level 3 hospitals
Number of subjects: 0
Study 6242491 — intervention group
Group type: EXPERIMENTAL
Intervention: Perinatal interventions
Number of subjects: 0
Study 6242491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal intensive care
Number of subjects: 0
Study 31470899 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU/d cholecalciferol (vitamin D3)
Number of subjects: 90
Study 31470899 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU/d cholecalciferol (vitamin D3)
Number of subjects: 90
Study 31470899 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 90
Study 27487783 — intervention group
Group type: COMPARATOR
Intervention: Treatment condition 1 (computer delivered risk assessment and feedback, nurse brief advice)
Number of subjects: 39
Study 27487783 — intervention group
Group type: COMPARATOR
Intervention: Treatment condition 2 (all elements of Treatment condition 1 plus biochemical feedback of infant SHS exposure)
Number of subjects: 39
Study 27487783 — intervention group
Group type: COMPARATOR
Intervention: Treatment condition 1
Number of subjects: 39
Study 27487783 — intervention group
Group type: COMPARATOR
Intervention: Treatment condition 2
Number of subjects: 39
Study 25458804 — intervention group
Group type: EXPERIMENTAL
Intervention: Care programme for challenging behaviour (education package and structured assessment tools)
Number of subjects: 380
Study 25458804 — intervention group
Group type: COMPARATOR
Intervention: Control measurements (no intervention)
Number of subjects: 380
Study 24524866 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with midazolam and fentanyl
Number of subjects: 73
Study 24524866 — intervention group
Group type: COMPARATOR
Intervention: No sedation
Number of subjects: 73
Study 22588253 — intervention group
Group type: EXPERIMENTAL
Intervention: Active THC (2.8% THC)
Number of subjects: 136
Study 22588253 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of having smoked THC
Number of subjects: 136
Study 22588253 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy of smoking THC in combination with active THC
Number of subjects: 136
Study 22588253 — intervention group
Group type: EXPERIMENTAL
Intervention: Active drug and expectancy
Number of subjects: 136
Study 22588253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 20850848 — intervention group
Group type: EXPERIMENTAL
Intervention: Moyo chart
Number of subjects: 61
Study 20850848 — intervention group
Group type: COMPARATOR
Intervention: Lookup tables
Number of subjects: 61
Study 18161677 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachial-basilic arteriovenous fistula (BB-AVF)
Number of subjects: 27
Study 18161677 — intervention group
Group type: COMPARATOR
Intervention: Prosthetic brachial-antecubital forearm loop access (PTFE)
Number of subjects: 27
Study 15899950 — intervention group
Group type: EXPERIMENTAL
Intervention: L-folic acid (7.5 mg/d)
Number of subjects: 20
Study 12789968 — intervention group
Group type: EXPERIMENTAL
Intervention: Product 2 (cetylpyridinium chloride)
Number of subjects: 99
Study 12789968 — intervention group
Group type: EXPERIMENTAL
Intervention: Product 1 (essential oils)
Number of subjects: 99
Study 12789968 — intervention group
Group type: EXPERIMENTAL
Intervention: Product 4 (chlorine dioxide plus zinc)
Number of subjects: 99
Study 12789968 — intervention group
Group type: COMPARATOR
Intervention: Product 3 (placebo)
Number of subjects: 99
Study 9814729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 100 microg b.d.
Number of subjects: 34
Study 9814729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9814729 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 34
Study 7544219 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant IGF-I (2 x 80 micrograms/kg body weight subcutaneously)
Number of subjects: 19
Study 7544219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 2689790 — intervention group
Group type: EXPERIMENTAL
Intervention: bioMérieux kit
Number of subjects: 0
Study 2689790 — intervention group
Group type: COMPARATOR
Intervention: Serono kit
Number of subjects: 0
Study 2689790 — intervention group
Group type: COMPARATOR
Intervention: micronized progesterone administration
Number of subjects: 0
Study 320111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zinc sulphate as adjuvant treatment
Number of subjects: 51
Study 320111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 320111 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma zinc levels in patients with idiopathic ulcerative colitis or proctitis
Number of subjects: 51
Study 31919527 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 22
Study 31919527 — intervention group
Group type: COMPARATOR
Intervention: Collagen Protein (CP)
Number of subjects: 22
Study 30448778 — intervention group
Group type: EXPERIMENTAL
Intervention: Online training counselling on safe sport participation every 3 months
Number of subjects: 357
Study 30448778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no online training counselling)
Number of subjects: 357
Study 30448778 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 357
Study 30448778 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 357
Study 28130349 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve fibre layer haemorrhages
Number of subjects: 133
Study 28130349 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotton wool spots
Number of subjects: 133
Study 28130349 — intervention group
Group type: EXPERIMENTAL
Intervention: Exudates
Number of subjects: 133
Study 28130349 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudodrusen
Number of subjects: 133
Study 25785804 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption (target blood alcohol concentration = .08%)
Number of subjects: 215
Study 23583458 — intervention group
Group type: EXPERIMENTAL
Intervention: IV aminophylline 3 mg/kg
Number of subjects: 90
Study 23583458 — intervention group
Group type: EXPERIMENTAL
Intervention: IV doxapram 1 mg/kg
Number of subjects: 90
Study 23583458 — intervention group
Group type: COMPARATOR
Intervention: Normal IV saline (control)
Number of subjects: 90
Study 21425378 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicory coffee (300 mL daily for 1 week)
Number of subjects: 27
Study 18005369 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive self-therapy (CST)
Number of subjects: 151
Study 18005369 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 151
Study 16616650 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% O2 in air
Number of subjects: 36
Study 16616650 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% N2O
Number of subjects: 36
Study 16616650 — intervention group
Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 36
Study 12562375 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable implant overdentures
Number of subjects: 13
Study 12562375 — intervention group
Group type: COMPARATOR
Intervention: Fixed prostheses
Number of subjects: 13
Study 10982198 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-100 mg)
Number of subjects: 236
Study 10982198 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20-40 mg)
Number of subjects: 236
Study 8973920 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week culture-specific dietary intervention
Number of subjects: 38
Study 8973920 — intervention group
Group type: COMPARATOR
Intervention: Distribution of health-related pamphlets
Number of subjects: 38
Study 1581012 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 to 50 mg, twice daily for 8 weeks)
Number of subjects: 23
Study 1581012 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (50 to 100 mg, twice daily for 8 weeks)
Number of subjects: 23
Study 1581012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 to 25 mg, twice daily for 8 weeks)
Number of subjects: 23
Study 1581012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2417649 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin
Number of subjects: 31
Study 2417649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 29514649 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual Care + Moral Reconation Therapy (MRT)
Number of subjects: 0
Study 29514649 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 27687360 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg dexamethasone
Number of subjects: 120
Study 27687360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative superhydration of lactated Ringer's solution (30 mL/kg per fasting time)
Number of subjects: 120
Study 27687360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dexamethasone and intraoperative superhydration
Number of subjects: 120
Study 27687360 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone group
Number of subjects: 120
Study 27687360 — intervention group
Group type: COMPARATOR
Intervention: Superhydration group
Number of subjects: 120
Study 24770699 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐min brisk walking 1×/week (n = 10)
Number of subjects: 72
Study 24770699 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐min brisk walking 3×/week (n = 10)
Number of subjects: 72
Study 24770699 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min brisk walking 3×/week (n = 18)
Number of subjects: 72
Study 24770699 — intervention group
Group type: EXPERIMENTAL
Intervention: 60‐min brisk walking 3×/week (n = 10)
Number of subjects: 72
Study 24770699 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐min running 3×/week (n = 14)
Number of subjects: 72
Study 24770699 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 10)
Number of subjects: 72
Study 22272945 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made mouthguard (CM)
Number of subjects: 18
Study 22272945 — intervention group
Group type: COMPARATOR
Intervention: Boil-and-bite mouthguard (O-Flow™ Max Under Armour®) (UA)
Number of subjects: 18